Neuravi to Market EmboTrap Device
Neuravi has raised $21 million to support European commercialization of its EmboTrap revascularization device for acute ischemic stroke patients. The company also plans a clinical trial, Arise II, that will enroll patients in Europe and the U.S. this year, the Irish devicemaker said Wednesday.
The device, which features a dual-layer stent-like design, works by restoring blood flow to the brain.
Rapid intervention following a stroke is critical to the patient’s well-being. Ischemic strokes account for 87 percent of all strokes.
Fountain Healthcare Partners and Delta Partners provided funding. — Jason Scott